Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections
- 7 January 2019
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (1), 47-50
- https://doi.org/10.1182/bloodadvances.2018025858
Abstract
Key Points: Neutralization of IFN-γ with emapalumab can reverse severe, refractory hemophagocytic lymphohistiocytosis. Neutralizing IFN-γ did not impair control of multiple viral and other infections in a severely ill patient.Keywords
This publication has 19 references indexed in Scilit:
- Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumabPediatric Blood & Cancer, 2012
- Diagnostic Accuracy of a Specific Cytokine Pattern in Hemophagocytic Lymphohistiocytosis in ChildrenThe Journal of Pediatrics, 2012
- Expression of type I interferon by splenic macrophages suppresses adaptive immunity during sepsisThe EMBO Journal, 2011
- How I treat hemophagocytic lymphohistiocytosisBlood, 2011
- CXCR3 ligands: redundant, collaborative and antagonistic functionsImmunology & Cell Biology, 2011
- Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune DiseasesImmunity, 2009
- Neutralization of IFNγ defeats haemophagocytosis in LCMV‐infected perforin‐ and Rab27a‐deficient miceEMBO Molecular Medicine, 2009
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007
- Viruses Evade the Immune System through Type I Interferon-Mediated STAT2-Dependent, but STAT1-Independent, SignalingImmunity, 2005
- An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorderBlood, 2004